Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J BUON ; 14(3): 457-62, 2009.
Article in English | MEDLINE | ID: mdl-19810139

ABSTRACT

PURPOSE: This study was conducted to evaluate the quantitative assessment of HER2/neu immunohistochemical expression in urothelial bladder cancer in order to determine its prognostic significance. MATERIALS AND METHODS: Archival tumor tissue from 80 patients with primary urothelial carcinoma were analysed for HER2/neu immunohistochemical expression. A highly reproducible standardized procedure on a Bond-X automated slide stainer was used. RESULTS: HER2 protein was overexpressed in 41 of 80 patients (51.25%), demonstrating an increase in the expression rate corresponding to progressively advanced tumor stage (p=0.032) and tumor grade (p=0.0001). Kaplan-Meier analyses showed that positive membranous expression of HER2/neu was not associated with an increased probability of tumor recurrence (p=0.362). In contrast, HER2 scores correlated strongly with specific survival probability (p=0.002) and overall survival (p=0.025). Multivariate analysis revealed that only stage was an independent predictor of specific survival (p=0.016). HER2 expression was an independent predictor of specific survival with borderline statistical significance (p=0.08). CONCLUSION: HER2 overexpression represents a prognostic factor for adverse disease outcome.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma/mortality , Receptor, ErbB-2/metabolism , Urinary Bladder Neoplasms/mortality , Urothelium/metabolism , Aged , Carcinoma/metabolism , Carcinoma/pathology , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Prognosis , Proportional Hazards Models , Survival Analysis , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/pathology , Urothelium/pathology
4.
J BUON ; 12(4): 543-5, 2007.
Article in English | MEDLINE | ID: mdl-18067215

ABSTRACT

We report a rare case of a primary melanoma of the lung initially presenting with haemoptysis, which was diagnosed using 2 new immunohistochemistry markers and cytology with immunocytochemistry. A 67-year-old male underwent repeated major lung resections and died because of early recurrences of a primary pulmonary melanoma as detailed study excluded other primary foci. The diagnosis of the patient's last recurrence was achieved on a fine needle aspiration (FNA) specimen with immunocytochemistry. To the best of our knowledge this is the first case of primary pulmonary melanoma diagnosed by immunocytochemistry on FNA material.


Subject(s)
Antigens, Neoplasm/analysis , Biomarkers, Tumor/analysis , Lung Neoplasms/diagnosis , Melanoma/diagnosis , Neoplasm Proteins/analysis , Aged , Biopsy, Fine-Needle , Humans , Immunohistochemistry , Lung Neoplasms/pathology , MART-1 Antigen , Male , Melanoma/pathology
5.
Int J Tuberc Lung Dis ; 10(5): 588-90, 2006 May.
Article in English | MEDLINE | ID: mdl-16704045

ABSTRACT

In patients receiving anti-tumor necrosis factor (TNF) therapy, a probable exacerbation of latent tuberculosis (TB) is a major adverse event. The impairment of granuloma differentiation is considered a characteristic feature of TB in these patients. In this report we present three patients with rheumatic disease who developed TB under infliximab treatment. All of them had typical granulomas on the biopsy specimens, indicating that the expected impairment of granuloma formation is not always the case. The notion of granuloma-free TB in patients receiving anti-TNF therapy could shift a clinician's path away from performing a biopsy, thus delaying the establishment of a correct diagnosis.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Granuloma/immunology , Tuberculosis, Pulmonary/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Aged , Arthritis, Rheumatoid/complications , Bronchoscopy , Female , Humans , Immunosuppression Therapy , Infliximab , Male , Middle Aged , Spondylitis, Ankylosing/complications , Spondylitis, Ankylosing/drug therapy , Tuberculosis, Pulmonary/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...